The prognostic value and biological functions of HFM1 in breast cancer
Aim: HFM1 has been reported to be associated with meiosis and ovarian insufficiency, but its role in tumors remains unknown. This study aims to explore the functions and potential mechanism of HFM1 in breast cancer. Methods: Several databases, protein-protein interactions, gene ontology and the Kyoto Encyclopedia of Genes and Genomes were used for bioinformatic analysis. Tissue microarrays and cell viability assays were used to detect the expression of HFM1 and tamoxifen resistance, respectively. Results: HFM1 was downregulated in breast cancer with poor prognosis and may modulate DNA damage repair pathways and immune infiltration. Moreover, HFM1 may mediate ovarian steroidogenesis and participate in tamoxifen resistance of estrogen receptor-positive breast cancer cells. Conclusion: We presented a first study on biological functions and potential mechanisms of HFM1 in cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Epigenomics - 15(2023), 3 vom: 05. Feb., Seite 147-166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ying, Yingxia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.04.2023 Date Revised 03.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/epi-2023-0041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355250950 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355250950 | ||
| 003 | DE-627 | ||
| 005 | 20231226063945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/epi-2023-0041 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355250950 | ||
| 035 | |a (NLM)37020390 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ying, Yingxia |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The prognostic value and biological functions of HFM1 in breast cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2023 | ||
| 500 | |a Date Revised 03.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: HFM1 has been reported to be associated with meiosis and ovarian insufficiency, but its role in tumors remains unknown. This study aims to explore the functions and potential mechanism of HFM1 in breast cancer. Methods: Several databases, protein-protein interactions, gene ontology and the Kyoto Encyclopedia of Genes and Genomes were used for bioinformatic analysis. Tissue microarrays and cell viability assays were used to detect the expression of HFM1 and tamoxifen resistance, respectively. Results: HFM1 was downregulated in breast cancer with poor prognosis and may modulate DNA damage repair pathways and immune infiltration. Moreover, HFM1 may mediate ovarian steroidogenesis and participate in tamoxifen resistance of estrogen receptor-positive breast cancer cells. Conclusion: We presented a first study on biological functions and potential mechanisms of HFM1 in cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HFM1 | |
| 650 | 4 | |a bioinformatics analysis | |
| 650 | 4 | |a human breast cancer | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a tamoxifen resistance | |
| 650 | 7 | |a Tamoxifen |2 NLM | |
| 650 | 7 | |a 094ZI81Y45 |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a HFM1 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.6.1.- |2 NLM | |
| 650 | 7 | |a DNA Helicases |2 NLM | |
| 650 | 7 | |a EC 3.6.4.- |2 NLM | |
| 700 | 1 | |a Meng, Yiling |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Meichao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Pingting |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Suning |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Dong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Epigenomics |d 2009 |g 15(2023), 3 vom: 05. Feb., Seite 147-166 |w (DE-627)NLM19811866X |x 1750-192X |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:3 |g day:05 |g month:02 |g pages:147-166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/epi-2023-0041 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 3 |b 05 |c 02 |h 147-166 | ||